Celularity Confirms Commercialization Agreement with BioCellgraft for the Manufacture and Distribution of Advanced Biomaterial Products for Use in Oral Healthcare
- None.
- None.
Insights
The strategic commercialization agreement between Celularity Inc. and BioCellgraft, Inc. is poised to influence the dental and oral healthcare market significantly. This collaboration leverages Celularity's manufacturing capabilities with BioCellgraft's distribution network, potentially increasing market penetration for advanced biomaterial products. The dental/oral healthcare sector is experiencing substantial growth due to technological advancements and increased awareness of oral health.
From a market perspective, this agreement may lead to an expansion of product offerings and could serve as a growth catalyst for Celularity, given the large addressable market in periodontology, implant dentistry and oral surgery. Investors should monitor Celularity's operational capacity to meet the expected increase in demand and BioCellgraft's effectiveness in market penetration and distribution.
Entering into an exclusive U.S. strategic commercialization agreement typically has a positive impact on a company's financial outlook. For Celularity, this deal could result in increased revenues through the manufacturing of biomaterial products for a growing market. The exclusivity of the agreement ensures that Celularity is the sole manufacturer for BioCellgraft's distribution in the U.S., potentially leading to a stable and predictable revenue stream.
Investors should evaluate the terms of the agreement, such as the duration, revenue-sharing structure and any milestones or minimum purchase requirements, as these will influence the financial impact. Additionally, the agreement may enhance investor confidence in Celularity's strategic direction and operational execution, possibly affecting the company's stock valuation.
The partnership between Celularity and BioCellgraft underscores a strategic move within the biotechnology industry to capitalize on niche markets like dental/oral healthcare. The focus on allogeneic cell therapies and advanced biomaterials reflects an industry trend towards innovative solutions that can disrupt traditional healthcare practices.
It's crucial to assess the competitive landscape and the uniqueness of Celularity's biomaterial products. If their offerings demonstrate superior efficacy or cost-effectiveness, this could lead to a competitive advantage. Long-term, the success of this agreement depends on the clinical outcomes and patient satisfaction with the products used in dental procedures. Positive results could establish Celularity as a key player in this segment of the biotech industry.
FLORHAM PARK, N.J., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (the “Company”) a biotechnology company developing allogeneic cell therapies and advanced biomaterial products, today confirmed that it has entered into an exclusive U.S. strategic commercialization agreement with BioCellgraft, Inc. (“BioCellgraft”) under which Celularity will manufacture advanced biomaterial products for BioCellgraft which BioCellgraft will distribute in the United States for use in multiple dental/oral healthcare applications. A copy of BioCellgraft’s announcement of the agreement can be accessed here: https://www.prweb.com/releases/biocellgraft-finalizes-commercialization-agreement-with-celularity-for-the-manufacture-and-distribution-of-products-for-therapeutic-use-in-oral-healthcare-302025082.html.
Robert J. Hariri, M.D., Ph.D., Chairman, Chief Executive Officer, and founder of Celularity, said, “This commercialization agreement with BioCellgraft opens an important pathway for Celularity-manufactured, BioCellgraft-branded and marketed advanced biomaterial products into dental and oral healthcare applications in the United States that include periodontology, implant dentistry and oral surgery, all of which are large and growing markets.”
Forward-Looking Statements
This press release includes “forward-looking statements” within the meaning of The Private Securities Litigation Reform Act of 1995, as well as within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical facts are “forward-looking statements,” including those relating to future events. In some cases, you can identify forward-looking statements by terminology such as “anticipate,” “believe,” “can,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “forecast,” “intends,” “may,” “might,” “outlook,” “plan,” “possible,” “potential,” “predict,” “project,” “seek,” “should,” “strive,” “target,” “will,” “would” and the negative of terms like these or other comparable terminology, and other words or terms of similar meaning. The forward-looking statements in this press release include statements regarding The Company’s ability to sufficiently capitalize itself through cash flow from its manufactured biomaterial products, technical operations expertise, and cell banking activities, among others. Many factors could cause actual results to differ materially from those described in these forward-looking statements, including but not limited to: the regulatory status of its biomaterial products; the Company’s ability to develop and maintain sales and marketing capabilities, whether alone or with potential future collaborators; the risks associated with the Company’s current liquidity as well as developments relating to the Company’s competitors and industry, along with those risk factors set forth under the caption “Risk Factors” in The Company’s annual report on Form 10-K filed with the Securities and Exchange Commission (SEC) on March 31, 2023, and other filings with the SEC. If any of these risks materialize or underlying assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. There may be additional risks that The Company does not presently know, or that The Company currently believes are immaterial, that could also cause actual results to differ from those contained in the forward-looking statements. In addition, these forward-looking statements reflect The Company’s current expectations, plans, or forecasts of future events and views as of the date of this communication. Subsequent events and developments could cause assessments to change. Accordingly, forward-looking statements should not be relied upon as representing the Company’s views as of any subsequent date, and the Company undertakes no obligation to update forward-looking statements to reflect events or circumstances after the date hereof, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws.
Celularity Investor Contacts:
Carlos Ramirez, SVP, Investor Relations
Celularity Inc.
carlos.ramirez@celularity.com
FAQ
What is the recent announcement from Celularity Inc. (CELU)?
What are the specific areas of focus for the agreement between Celularity Inc. and BioCellgraft, Inc.?
Who is the Chairman, Chief Executive Officer, and founder of Celularity Inc.?
What is the ticker symbol for Celularity Inc.?
Where can the announcement of the agreement be accessed?
